IP Verse

Anavex Life Sciences competitive analysis

Latest publications and patents of Anavex Life Sciences New

Explore the latest publications and patents granted to Anavex Life Sciences, showcasing their recent innovations and technological advancements.

Last updated on: Sep 28, 2025

Publication Number	Publication Date	Title	Legal Status
Get instant update for new patents of Anavex Life Sciences
EP3324956	Nov 20, 2024	Enantiomers Of Tetrahydro-N,N-Dimethyl-2,2-Diphenyl-3-Furanmethanamine (Anavex2-73) And Use Thereof In The Treatment Of Alzheimer'S Disease And Other Disorders Modulated By The Sigma 1 Receptor	Granted And Under Opposition
EP3407880	Aug 17, 2022	Neurodevelopmental Disorder Therapy	Opposition Rejected

Latest patents of Anavex Life Sciences opposed by its competitors

Explore Anavex Life Sciences's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 2, 2025

Patent Number	Grant Date	Title	Total Oppositions
EP3324956	Nov 20, 2024	Enantiomers Of Tetrahydro-N,N-Dimethyl-2,2-Diphenyl-3-Furanmethanamine (Anavex2-73) And Use Thereof In The Treatment Of Alzheimer'S Disease And Other Disorders Modulated By The Sigma 1 Receptor	1
EP3407880	Aug 17, 2022	Neurodevelopmental Disorder Therapy	1

Latest PTAB cases involving Anavex Life Sciences

Discover the latest PTAB cases involving Anavex Life Sciences, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Anavex Life Sciences with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced	Strategy Type
ANAVEX LIFE SCIENCES	-	2	-	-	Non-Active
ELKINGTON AND FIFE	87	-	-	-	Highly Aggressive
SANDOZ	114	15	19	-	Highly Aggressive